Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
19.6M
-
Shares change
-
+7.27M
-
Total reported value, excl. options
-
$211M
-
Value change
-
+$82.1M
-
Put/Call ratio
-
0.3
-
Number of buys
-
59
-
Number of sells
-
-17
-
Price
-
$10.73
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q1 2018
90 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q1 2018.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.6M shares
of 77M outstanding shares and own 25.51% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.46M shares), Cormorant Asset Management, LP (1.88M shares), RA CAPITAL MANAGEMENT, LLC (1.53M shares), MILLENNIUM MANAGEMENT LLC (1.4M shares), BlackRock Inc. (1.21M shares), VANGUARD GROUP INC (1.15M shares), SPHERA FUNDS MANAGEMENT LTD. (1.03M shares), Rock Springs Capital Management LP (975K shares), Marshall Wace North America L.P. (857K shares), and PERCEPTIVE ADVISORS LLC (715K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.